Study of Efficacy,Safety and Tolerability of Ayurvedic Formulation in participants with Diabetic Kidney Disease

Dr Aparna Sathe0 个研究点目标入组 99 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Adult ( >18 yrs) either gender with prior diagnosis of DKD.
•2. Known case of Type 2 DM diagnosed at least since 6 months.
•3. CKD stage 3
•3 a : e GFR (EPI) 45 to < 60
•3 b : e GFR (EPI) 30 to < 45
•4. Participants on stable and acceptable dose of ACE inhibitors or ARB (angiotensin II receptor blockers)

•1)Type I DM
•2)Lack of clinical evidence or suspicion of renal diagnosis other than DKD
•3)UACR > 5000mg/g on any major measurement during screening.
•4)Uncontrolled Diabetes (HB1Ac > 8%)
•5)ESRD receiving dialysis or Anticipated progression to ESRD within treatmentperiod.
•6)Status postrenal transplant.
•7)Unstable CVD
•8)Other concomitant disease that could impair patients safety or ability to participate in study.
•9)Known case of Immunocompromised patients or subjects on immunorupressive drugs.
•10)Pregnant and lactating females.

发起方

Dr Aparna Sathe